Not a good buy right now: the stock is trading essentially exactly at the announced acquisition price ($15.50), which caps upside while leaving downside if the deal is delayed/changed/breaks.
Sentiment is net negative (hedge funds and insiders selling), which is typical into a takeout but still weak for a fresh entry.
With no Intellectia buy signal and limited merger-arb spread, the risk/reward is unfavorable for an impatient buyer looking for near-term upside.

Technical Analysis

Price is pinned around $15.50 and sitting near the pivot (15.553), suggesting a range-bound/takeout-anchored tape rather than a trending setup.
MACD histogram is negative (-0.169) but contracting: downside momentum is fading, yet it’s not a clean bullish reversal.
RSI(6) ~59.7: neutral-to-slightly bullish, not overbought.
Key levels: Support S1 15.465 / S2 15.411; Resistance R1 15.641 / R2 15.695. With a $15.50 deal price, these levels mainly define small arbitrage wiggles.
Pattern-based forward odds show modest upside probabilities (next day +1.32%, next week +3.95%, next month +9.46%), but those are likely less relevant under an acquisition “price magnet.”

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest put/call ratio = 1.35: positioning skews defensive/bearish (more puts than calls outstanding).
Options volume is extremely light (total volume 3; call volume 0, put volume 3), so sentiment signals from volume are weak/low-confidence.
Today’s open interest is elevated vs its 30-day average (today_vs_open_interest_avg_30_day ~112.59), suggesting positioning is in place, but not actively being traded today.
IV metrics are very low by percentile/rank (IV percentile ~1.99; IV rank ~1.24), consistent with a market expecting limited movement—also typical when a takeout price anchors the stock.

Technical Summary

Sell

Buy

Positive Catalysts

- Event-driven: Acquisition agreement with Sanofi at $15.50/share (deal value ~ $2B) provides a clear price anchor and potential path to cash-out at the stated price if it closes.
- Fundamentals (last reported quarter) show strong growth (revenue, earnings, margins), supporting business quality even though the deal now dominates price action.
- Upcoming calendar: QDEC 2025 earnings on 2026-02-25 (After Hours).

Neutral/Negative Catalysts

- Upside is capped: stock already trades at the stated takeout price ($15.50), leaving little/no spread for a new buyer.
- Deal risk: any regulatory/financing/timing issues or renegotiation could create meaningful downside from the takeout level.
- Trading trends show distribution: Hedge funds are selling (selling up 122.60% QoQ) and insiders are selling (selling up 283.68% MoM).
- Specific insider action/news: David Novack sold 114,000 shares (～$1.8M), reducing ownership to 63,344 shares (reported 2026-01-30).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $94.876M, +17.67% YoY (solid top-line growth).
Net income: $26.927M, +53.05% YoY (profitability accelerating).
EPS: $0.20, +81.82% YoY (strong earnings leverage).
Gross margin: 84.82%, +1.25% YoY (already high, improving further).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided in the dataset, so a recent trend assessment cannot be confirmed from the inputs.
Wall Street-style pros (based on provided info): strong YoY growth in revenue/EPS and a defined takeout price.
Wall Street-style cons (based on provided info): limited upside at the deal price and asymmetric downside if the acquisition does not close as expected.
Congress/influential trading check: No recent congress trading data available.

3 Analyst Rating

Wall Street analysts forecast DVAX stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 15.500

Low

Averages

20.5

High

Current: 15.500

Low

Averages

20.5

High

Citizens JMP

Roy Buchanan

Outperform

maintain

$31 -> $32

AI Analysis

2025-08-08

Reason

Citizens JMP

Roy Buchanan

Price Target

$31 -> $32

AI Analysis

2025-08-08

maintain

Outperform

Reason

Citizens JMP analyst Roy Buchanan raised the firm's price target on Dynavax to $32 from $31 and keeps an Outperform rating on the shares. Dynavax continues to focus on priorities in HEPLISAV-B, business development, and the pipeline with the board battle behind it, the analyst tells investors in a research note.

Goldman Sachs

Paul Choi

Strong Sell

Maintains

$12 → $10

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$12 → $10

2025-04-17

Maintains

Strong Sell

Reason

DVAX Should I Buy

DVAX Should I Buy

Should You Buy Dynavax Technologies Corp (DVAX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch